Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma

NCT00816959 is registered in ClinicalTrials.gov with American Scitech International as lead sponsor.

NCT NCT00816959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00816959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma
Lead sponsor
American Scitech International
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2011
Completion date
April 30, 2014
Enrollment
1,200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin's lymphoma